Dyve Biosciences, Inc (Dyve) is a clinically validated biotech with assets in immunology and oncology. Dyve develops novel small molecule and biologic drugs by leveraging its proprietary technology platform to design drug candidates in clinically optimized, patient-friendly, topically delivered dosage forms. Our patented emulsion chemistry delivers a broad range of molecules never before possible and does so with needle like speed and bioavailability, turning the skin tissue into a tunable drug delivery portal for locally optimized or systemic delivery.
Dyve’s lead programs target acidic microenvironments to treat immunological and oncological diseases. Our patented approach to pH modulation, leveraging decades of scientific breakthroughs that have not been translatable to humans, increases the pH of an acidic microenvironment, effectively reversing the extracellular conditions that lead to disease progression.
Dyve’s lead programs target acidic microenvironments to treat immunological and oncological diseases. Our patented approach to pH modulation, leveraging decades of scientific breakthroughs that have not been translatable to humans, increases the pH of an acidic microenvironment, effectively reversing the extracellular conditions that lead to disease progression.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Immunology
Lead Product in Development:
DYV700 for the treatment of acute gouty arthritis
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
DYV700 (gout), DYV600 (melasma), DYV350 (adipolysis)
Speaker
